Xiuhong Wang

Prof. Xiuhong Wang

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
TYTieshan Yang
Tieshan Yang
QYQian Yao
Qian Yao
FCFei Cao
Fei Cao
QLQianqian Liu
Qianqian Liu
BLBinlei Liu
Binlei Liu
XWXiuhong Wang
Xiuhong Wang
Silver nanoparticles inhibit the function of hypoxia-inducible factor-1 and target genes: insight into the cytotoxicity and antiangiogenesis Tieshan Yang,1 Qian Yao,1 Fei Cao,1 Qianqian Liu,1 Binlei Liu,2 Xiu-Hong Wang1 1Laboratory for Biomedical Photonics, Institute of Laser Engineering, Beijing University of Technology, 2Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China Hypoxia-inducible factor-1 (HIF-1) is a transcription factor that is activated upon exposure to hypoxic stress. It modulates a number of cellular responses including proliferation, apoptosis, angiogenesis, and metabolism by activating a panel of target genes in response to hypoxia. The HIF-1 level is often upregulated in the hypoxic microenvironment of solid tumors, which contributes to cancer treatment failure. Here we report that silver nanoparticles (AgNPs), which are widely used as an antimicrobial agent, are an effective inhibitor of HIF-1. AgNPs inhibited the activation of a HIF-dependent reporter construct after the cells were exposed to hypoxic conditions or treated with cobalt chloride, a hypoxia mimetic agent. The AgNPs also interfered with the accumulation of HIF-1α protein and the induction of the endogenous HIF target genes, VEGF-A and GLUT1. Since both HIF-1 and vascular endothelial growth factor-A play an important role in angiogenesis, AgNPs also inhibited angiogenesis in vitro. Our data reveal a new mechanism of how AgNPs act on cellular function, that is, they disrupt HIF signaling pathway. This finding provides a novel insight into how AgNPs can inhibit cancer cell growth and angiogenesis. Keywords: silver nanoparticles (AgNPs), hypoxia-inducible factor, transcriptional activity, vascular endothelial growth factor-A, angiogenesis

5 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
YWYaping Wang
Yaping Wang
MLMarion C. Lang
Marion C. Lang
JLJinsong Lu
Jinsong Lu
MSMingqian Suo
Mingqian Suo
MDMengcong Du
Mengcong Du
PWPu Wang
Pu Wang
Single cell analysis is crucial for elucidating cellular diversity and heterogeneity as well as for medical diagnostics operating at the ultimate detection limit. Although superbly sensitive biosensors have been developed using the strongly enhanced evanescent fields provided by optical microcavities, real-time quantification of intracellular molecules remains challenging due to the extreme low quantity and limitations of the current techniques. Here, we introduce an active-mode optical microcavity sensing stage with enhanced sensitivity that operates via Förster resonant energy transferring (FRET) mechanism. The mutual effects of optical microcavity and FRET greatly enhances the sensing performance by four orders of magnitude compared to pure Whispering gallery mode (WGM) microcavity sensing system. We demonstrate distinct sensing mechanism of FRET-WGM from pure WGM. Predicted lasing wavelengths of both donor and acceptor by theoretical calculations are in perfect agreement with the experimental data. The proposed sensor enables quantitative molecular analysis at single cell resolution, and real-time monitoring of intracellular molecules over extended periods while maintaining the cell viability. By achieving high sensitivity at single cell level, our approach provides a path toward FRET-enhanced real-time quantitative analysis of intracellular molecules.

1 February 2020 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
PQPengfei Qiao
Pengfei Qiao
XWXiuhong Wang
Xiuhong Wang
SGShoufei Gao
Shoufei Gao
XYXiaoyan Yin
Xiaoyan Yin
YWYingying Wang
Yingying Wang
PWPu Wang
Pu Wang

7 September 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
XMXiaotong Meng
Xiaotong Meng
XWXiuhong Wang
Xiuhong Wang
ZCZhaochen Cheng
Zhaochen Cheng
NTNan Tian
Nan Tian
MLMarion C. Lang
Marion C. Lang
PWPu Wang
Pu Wang

29 July 2020 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
FHFang He
Fang He
HJHuai-Qiang Ju
Huai-Qiang Ju
YDYi Ding
Yi Ding
ZJZhiqiang Jiang
Zhiqiang Jiang
ZLzhenhui Li
zhenhui Li
XWXiangbo Wan
Xiangbo Wan
Background: For patients with locally advanced rectal cancer (LARC), it is unclear whether neoadjuvant chemoradiotherapy-induced pathologic complete response (pCR) individuals would further benefit from adjuvant chemotherapy (ACT). Methods: The pCR individuals who received different ACT cycles were paired by propensity score matching. Overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were calculated by Kaplan–Meier and log-rank test. Results: In total, 1041 pCR individuals were identified from 5567 LARC cases. Specifically, 303 pCR cases had no ACT treatment, and 738 pCR patients received fluoropyrimidine-based ACT (median, 4 cycles) treatment. After 1:3 propensity score matching, 297 cases without ACT treatment were matched to 712 cases who received ACT treatment. Kaplan–Meier analysis showed that pCR individuals treated with or without ACT had the similar 3-year outcome (OS, DFS, LRFS and DMFS) (all P > 0.05). Moreover, the pCR patients received different ACT cycle(s) (0 vs. 1–4 cycles, 0 vs. ≥5 cycles) had comparable 3-year OS, DFS, LRFS and DMFS (all P > 0.05). In stratified analysis, ACT treatment did not improve 3-year survival (OS, DFS, LRFS and DMFS) for the baseline high-risk (cT3–4/cN1–2) subgroup patients (all P > 0.05). Conclusion: ACT, which did not improve survival, is unnecessary to neoadjuvant treatment-induced pCR LARC patients. Trial registration: 2019ZSLYEC-136 (24-6-2019).

24 October 2022 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
XZXuegang Zhang
Xuegang Zhang
FCFei Chen
Fei Chen
YJYijian Jiang
Yijian Jiang
YYYan Yinzhou
Yan Yinzhou
LYLixue Yang
Lixue Yang
QWQiang Wang
Qiang Wang